Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axcan Pharma US Inc.

Division of Allergan PLC

Latest From Axcan Pharma US Inc.

Xenon appoints Steve Gannon to board

Xenon Pharmaceuticals, a clinical-stage biopharmaceutical company, has named Steven Gannon to its board of directors; he will also serve on the company's audit committee. Mr Gannon is a senior financial executive whose executive and board experience spans the pharmaceutical industry, and includes corporate finance and strategic transactions, mergers and acquisitions, business and corporate development and commercial operations. His past executive experience includes serving as chief financial officer, senior vice-president of finance, and treasurer at Aptalis Pharma (formerly Axcan Pharma). 

Companies

Par-Endo $8bn merger makes Mylan look undervalued

In a deal that proves just what can be done when all shareholders can be consulted in a single elevator journey, Endo International and privately owned Par Pharmaceutical have put together a $8.05bn merger to create the fifth largest independent company in the generics pharmaceutical space. And the deal makes Teva's bid for Mylan look somewhat underpowered.

Orthopedics Respiratory

Forest Builds On Saunders’ Strategy With $2.9B Aptalis Buy

The specialty pharma makes its first acquisition of the New Year, tucking in gastrointestinal and cystic fibrosis franchises, which bolster its current therapeutic area offerings.

BioPharmaceutical North America

BioNotebook: TPG's Aptalis files for $500 million IPO, Shire extends offer for ViroPharma

The days before and after Christmas weren’t completely devoid of news. A pair of companies announced plans for initial public offerings, including an IPO for private equity-backed Aptalis. An antibacterial drug developer raised $18 million in a private financing, while a company testing a multiple sclerosis therapy raised $8 million in a secondary offering. A small oncology specialist said it raised more than $3 million in an add-on offering. And Shire extended its tender offer for the $4.2 billion takeover of ViroPharma.

Infectious Diseases Cancer
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register